Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study - 03/09/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | In a real-world setting, therapeutic drug monitoring of CT-P13 was applied in 70.7% of patients. |
• | Therapeutic drug monitoring of infliximab was collected in a proactive approach in two-thirds of patients. |
• | The presence of anti-CT-P13 antibody was observed in 15.9% of patients with a drug-sensitive assay. |
• | The presence of ACA was associated with a lower rate of CT-P13 trough concentration. |
Summary |
Background |
Whether therapeutic drug monitoring (TDM) of infliximab should be implemented in daily practice is an ongoing controversy.
Aims |
To assess the real-world use of TDM in an observational multicentre cohort study with consecutive patients with inflammatory bowel disease (IBD) treated with CT-P13.
Methods |
Between September 2015 and December 2016, 364 patients with IBD were treated with CT-P13 in 13 gastroenterology departments and were followed up for 54 weeks. Disease activity, CT-P13 trough concentration and anti-CT-P13 antibody (ACA) were recorded.
Results |
Steroid-free clinical remission rates at week 54 were 67.0% and 56.4% in patients with CD and UC, respectively. CT-P13 trough concentrations were measured in 70.7% of the patients. The mean CT-P13 trough concentration was 4.2±4.3μg/mL. The presence of ACA was observed in 53 (15.9%) patients. CT-P13 trough concentration was collected in a proactive approach in 62.8% of cases and in a reactive approach in 37.2%. Among patients who submitted to TDM, CT-P13 therapy was optimized in 88.7% of the reactive group and in 22.5% of the proactive group (P<0.001).
Conclusion |
In a real-world cohort of patients with IBD treated with CT-P13, more than two-thirds of the patients underwent TDM. CT-P13 optimization was much less common in the proactive approach than in the reactive approach.
Le texte complet de cet article est disponible en PDF.Keywords : Crohn's disease, Ulcerative colitis, Inflammatory bowel disease, Infliximab, Biosimilar, CT-P13
Abbreviations : CD, UC, IBD, TNF, CRP
Plan
Vol 44 - N° 4
P. 609-618 - septembre 2020 Retour au numéro
Article précédent
- Efficacy and safety of islet autotransplantation after total pancreatectomy in chronic pancreatitis: A systematic review and meta-analysis including 17 studies
- Ya-Jun Zhang, Dan-Dan Duan, Hang Yuan
- Prevalence of gallstone in Mainland China: A meta-analysis of cross-sectional studies
- Zhou Su, Yahui Gong, Zhihai Liang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?